Publication date: Apr 12, 2019
The FDA’s safety announcement this week that says it has identified harm reported from sudden discontinuation of opioid pain medicines and is requiring label changes to guide prescribers on gradual, individualized tapering was generally praised.
-As several past presidents of the American Academy of Pain Medicine and other prominent medical professionals have pointed out in a December 2018 letter to the Governor of Oregon, there are no published trials data that establish benefit to legacy patients from mandated tapering of opioid therapy.
-I cannot believe that these -findings” were a surprise to anyone that deals with opioids,” wrote Dr. Mark Helfand to the National Pain Report.
Gary lives in Virginia and wrote to the National Pain Report that the FDA word getting out needs to happen fast.
- WCG targets pain management, opioid alternatives in Analgesic Solutions deal
- FDA: Opioid Med Labels Will Include More Info on Appropriate Tapering in Physically Dependent Patients
- Integrating Adjuvant Analgesics into Perioperative Pain Practice: Results from an Academic Medical Center.
- Opioid Versus Nonopioid Analgesia After Carpal Tunnel Release: A Randomized, Prospective Study.
- Mixed Mu-Nociceptin/Orphanin FQ opioid receptor agonists and the search for the analgesic holy grail.
- Pain Management in Trauma Patients Affected by The Opioid Epidemic: A Narrative Review.